Analysis cut-off date: September 30, 2015.
Treatment Arm
Median
(95% CI), mo
Rate at
1 y
HR
a
(95% CI)
P
Pembro 2 mg/kg
10.4 (9.4-11.9) 43.2% 0.71 (0.58-0.88) 0.0008
Pembro 10 mg/kg 12.7 (10.0-17.3) 52.3% 0.61 (0.49-0.75) <0.0001
Docetaxel
8.5 (7.5-9.8)
34.6%
—
—
a
Comparison of pembrolizumab vs docetaxel.
0
5
10
15
20
25
0
10
20
30
40
50
60
70
80
90
100
Time, months
Overall
Survival, %
344
346
343
259
255
212
115
124
79
49
56
33
12
6
1
0
0
0
2 vs 10 mg/kg:
HR 1.17, 95% CI 0.94-1.45
OS a 1 año: 43%-52%
OS PD-L1 TPS ≥1% Stratum
Beneficio en supervivencia clínicamente relevante y
estadísticamente significativo en pacientes con
expresión de PD-L1 ≥1%
Herbst RS et al.
Lancet
2016; 387: 1540–1550 (and online appendix).
